Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway
Frontiers in Endocrinology · 2026
DOI: 10.3389/fendo.2026.1739944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Nan Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Flavanones, Thyroid Neoplasms, Proto-Oncogene Proteins, MAP Kinase Kinase Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Papillary thyroid cancer (PTC) is the most common type of endocrine malignancy caused by genetic mutations, hormonal imbalances, and environmental factors. However, recurrent infections, and metastasis in PTC patients remain challenged due to complexity of traditional methods. Baicalein (BA) is a kind of natural flavonoid that exhibits the anti-cancer, anti-inflammatory, anti-tumor, and anti-viral activities. The molecular mechanism of baicalein in pathogenesis of PTC remains unclear. This study was designed to explore the inhibitory effects of BA against PTC by mediating the Golgi apparatus reprogramming via PLAU and suppressing the TPL2/MEK2/ERK2 pathway.
Methods
Transcriptomic analysis was performed to explore the gene expression profiles. Molecular docking was employed to identify the potential targets to elucidate the molecular mechanism of action of BA.
Results
PLAU, an up-regulated DEG, is implicated in tumor development, lymph node metastasis, and infiltration levels of neutrophils and dendritic cells in thyroid cancer patients. Molecular docking analysis revealed that serum levels of uPA protein encoded by PLAU and Plau mRNA were elevated in PTC patients with metastasis and BRAF mutation. BA treatment upregulates PLAU gene expression, but this increased PLAU protein subsequently interacts with and inhibited by BA, leading to downstream pathway suppression.
Conclusion
It was concluded it could be served as a promising therapeutic strategy for the treatment of PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
- Respiratory Medicine, Shenzhen Pingle Orthopedic Hospital, Shenzhen, China.
Zitieren
APA
Wu, N., Wu, Y., Zhang, Q., Naeem, M., Jing, R., Luo, Y. B., & Yi, S. (2026). Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1739944
Vancouver
Wu N, Wu Y, Zhang Q, Naeem M, Jing R, Luo YB, et al. Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1739944
BibTeX
@article{Wu2026,
author = {Wu, Nan and Wu, Yang and Zhang, Qian and Naeem, Muhammad and Jing, Ren and Luo, Yuan-Bin and Yi, Shijian},
title = {Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway},
journal = {Frontiers in Endocrinology},
year = {2026},
doi = {10.3389/fendo.2026.1739944}
}
EUVIMED